BCIs are not science fiction. They are not twenty years away. Cochlear implants — a form of BCI — are already used by over 700,000 people worldwide. Deep brain stimulation treats Parkinson's disease in hundreds of thousands of patients. A paralysed patient in 2023 decoded speech at 80 words per minute using a brain implant alone. The gap is between that clinical reality and the broader narrative of uploading consciousness, augmenting healthy brains, or plugging directly into the internet.
A brain-computer interface (BCI) is a direct communication pathway between the brain's electrical activity and an external device, bypassing muscles, nerves, and speech entirely. Neurons produce measurable electrical signals; BCIs capture those signals using electrodes placed on or inside the brain, decode them using signal-processing algorithms, and translate them into commands for computers, robotic limbs, or communication software. BCIs range from non-invasive EEG headsets worn on the scalp to surgically implanted electrode arrays that read individual neuron firing.
1 What Is a Brain-Computer Interface?
A brain-computer interface is a direct communication pathway between the brain's electrical activity and an external device — bypassing muscles, nerves, and speech entirely.
The brain generates electrical signals whenever neurons fire. These signals form patterns that correspond to thoughts, intentions, and movements. BCIs read those patterns, decode what the brain is trying to do, and execute it on an external system — moving a cursor, controlling a robotic arm, or generating synthesised speech.
The brain has approximately 86 billion neurons. Current implants can read from hundreds to a few thousand at best. Decoding intent from this partial picture requires significant inference, pattern recognition, and machine learning — the signal is always an incomplete sample of an extraordinarily complex system.
2 How Does a BCI Actually Connect to the Brain?
There are three main approaches, and the trade-off in every case is the same: the closer to the neurons, the better the signal — and the higher the risk.
Electrodes placed on the scalp pick up broad electrical activity. Easy to wear, widely accessible, no surgical risk — but signal quality is poor, like listening to a conversation through a thick wall. Used for meditation feedback, basic control tasks, and research. Consumer brands like Emotiv and Muse operate in this category.
Electrodes placed on the surface of the brain — under the skull but not penetrating tissue. Significantly better signal than EEG. Used clinically in epilepsy monitoring and in experimental motor and speech restoration systems. Middle ground between accessibility and performance.
Electrodes inserted directly into brain tissue. Highest signal resolution — can read individual neuron firing. This is what Neuralink, Blackrock Neurotech, and most advanced research BCIs use. Long-term stability is a significant challenge: brain tissue reacts to foreign objects, forming scar tissue that weakens signal quality over time.
3 What Has Actually Been Achieved?
Medical BCIs — Real, Approved, and in Use
The most widely deployed BCI in the world. Converts sound into electrical signals sent directly to the auditory nerve, bypassing damaged hair cells in the inner ear. Mature, mass-deployed technology — the proof of concept for what BCIs can achieve at scale.
Electrodes implanted in specific brain regions deliver controlled electrical pulses. Used to treat Parkinson's disease, essential tremor, dystonia, and in some cases treatment-resistant depression and OCD. This is not experimental — it is standard clinical practice in neurology.
Clinical trials have demonstrated paralysed patients controlling computer cursors, robotic arms, and on-screen keyboards using thought alone. The BrainGate consortium has been central to this work. Not yet approved as a consumer product — still in controlled research settings with small numbers of participants.
A Stanford-led team published results in 2023 showing a paralysed patient decoding intended speech at approximately 80 words per minute — a significant jump over prior benchmarks — using an implanted electrode array in the speech motor cortex. A separate UC San Francisco team achieved real-time speech synthesis from neural signals at conversational speeds.
Implanted its first human patient in early 2024 under an FDA-approved clinical trial called PRIME. Early results showed the patient controlling a computer cursor and playing chess using thought alone. Neuralink's long-term safety profile and data remain under ongoing monitoring — this is a trial, not a product.
4 What Are the Unsolved Problems?
Signal degradation over time: Implanted electrodes trigger a biological immune response. Scar tissue forms around them over months to years, progressively weakening signal quality. This is one of the most significant open challenges for long-term implants. New materials — softer, flexible electrodes; hydrogel coatings — are being researched to reduce the brain's reaction.
Bandwidth asymmetry: Current BCIs are far better at reading from the brain than writing back to it. Delivering precise sensory feedback — restoring the feeling of touch in a prosthetic hand — requires stimulating very specific neuron populations, which is much harder than recording. True bidirectional communication remains largely experimental.
Decoding complexity: Even with a good signal, translating neural activity into intent is a hard inference problem. Every person's neural patterns differ. Decoders trained on one individual rarely transfer to another. Calibration takes time, and the system can drift as neural representations shift with learning and experience.
Surgery risk: Any brain surgery carries risk of infection, bleeding, stroke, and anaesthesia complications. Acceptable for a patient with severe paralysis who gains transformative function. The risk calculus is very different for a healthy user seeking cognitive enhancement — and this is precisely why medical and consumer BCIs are on completely different timelines.
5 What Does the Development Timeline Actually Look Like?
Near-Term — Now to 5 Years
Continued clinical trial expansion for motor and speech BCIs in paralysis patients
Better electrode materials reducing signal degradation timelines
More FDA approvals in narrow therapeutic categories — DBS for new indications, speech restoration
Neural data privacy becoming a live policy and regulatory issue across jurisdictions
Medium-Term — 5 to 10 Years
Wireless, fully implantable BCIs becoming standard in approved medical devices
Early bidirectional sensory feedback in prosthetics — restoring some touch sensation
First regulated consumer-adjacent devices in specific accessibility niches
Significant reduction in implant surgery complexity and recovery time
Long-Term — Speculative (10+ Years)
High-bandwidth thought-to-text for healthy users, memory augmentation, and brain-to-AI direct interfaces are real research directions — not fiction. They remain far from viable outside controlled lab settings and depend on solving electrode stability, decoding complexity, and surgical risk simultaneously. These are the milestones the headlines announce; the near and medium-term milestones above are where the actual progress is happening.
The near-term story is restoration — giving back movement, speech, and sensation to people who have lost them. That is still a profound technology. Just a different one than the headlines often suggest.
— NeeAr Ventures Editorial
6 What Are the Ethics Questions BCIs Are Raising?
BCIs raise ethical questions that are qualitatively different from most other technologies — because what's being accessed is not a device or a database, but the brain itself.
Neural signals can reveal emotional states, attention levels, cognitive load, and early signs of neurological conditions — far more than the user intends to share. Unlike a password, neural data cannot be changed if compromised. Who owns it — user, company, insurer, employer — is legally unresolved in most jurisdictions.
The right to mental privacy was never legally protected because it was never thought to need protection. BCIs change that. If a device can read intentions before they become actions, who controls that access becomes an urgent question. Cognitive liberty is now an active legal concept, not a hypothetical.
Medical BCIs restore lost function. Enhancement BCIs would give additional capability to those who already have it. If BCIs can improve memory, attention, or processing speed, access will be unequal — with consequences for social mobility and meritocracy that go deeper than most existing inequalities.
Future high-integration BCIs may be far less reversible — either technically, because of deep neural integration, or practically, because a user becomes cognitively dependent on the augmentation. Informed consent for a device that may permanently alter cognition is a harder standard than for most medical interventions.
A networked BCI is potentially accessible to whoever controls the network. The scenarios range from an employer monitoring attention to a government reading the neural signals of dissidents. These follow directly from the architecture of networked devices and the economic incentives of the companies building them.
Deep brain stimulation already changes personality in some patients. If a BCI optimises for productivity, focus, or emotional stability, it is encoding a particular definition of a well-functioning mind — a value judgement made by engineers and companies, often without explicit acknowledgement.
Neurorights legislation is being developed in Chile and discussed in the EU. The EU's AI Act touches on some aspects of neural data. But comprehensive legal frameworks covering neural data ownership, cognitive liberty, and BCI corporate obligations do not yet exist globally — and the technology is moving faster than the policy response.
Non-invasive BCIs use electrodes on the scalp to detect brain activity without surgery, producing lower signal quality. Invasive BCIs place electrodes on or inside brain tissue through surgery, producing much higher signal resolution. The trade-off is always between signal quality and surgical risk.
Approved medical BCIs can treat Parkinson's disease via deep brain stimulation, restore hearing through cochlear implants, and in clinical trial settings allow paralysed patients to control computers and robotic limbs using thought alone. Speech BCIs have decoded intended speech at up to 80 words per minute in research settings. Consumer-grade BCIs are limited to basic EEG applications like meditation feedback and simple control tasks.
No. Neuralink is conducting an FDA-approved human clinical trial called PRIME Study, which began implanting patients in early 2024. It is not a commercial product. Participants are individuals with paralysis or ALS. Broader availability, if clinical trials succeed, would still require FDA approval as a medical device — a process that takes years.
In theory, yes — and this is an active long-term research direction. In practice, brain surgery risks currently make enhancement applications unjustifiable for healthy individuals. All approved and near-term BCI applications are therapeutic. Enhancement depends on solving electrode longevity, signal decoding accuracy, and surgical risk — none of which are solved problems today.
This is legally unresolved in most countries. Neural data can reveal emotional states, intentions, and cognitive patterns far beyond what users consciously choose to share. Most BCI companies retain data under general privacy policies not designed with neural signals in mind. Neurorights legislation being developed in Chile and discussed in the EU is an early attempt to create specific protections, but comprehensive legal frameworks do not yet exist globally.
There is currently no clear legal answer. Most BCI companies' data policies do not specifically address acquisition, bankruptcy, or shutdown scenarios. Neural data — unlike a password — cannot be revoked or changed once compromised, making the question of long-term custodianship more consequential than for most other types of personal data.